BioSpace News Archive

Kintara Therapeutics, Inc. (Nasdaq: KTRA) (“Kintara” or the “Company”), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced its participation in the Nasdaq Closing Bell Ceremony on May 19, 2023.

WBB Research Institute (WBBRI) hosted a Demi-Colton Virtual Salon on the need for a global response to Candida auris and other deadly pathogens.

BriaCell Therapeutics Corp. is pleased to announce that the Company has completed the previously-announced strategic investment by Prevail Partners, LLC in the Company, in accordance with a stock purchase agreement entered into between the Company and Prevail Partners on May 12, 2023.

Genmab A/S announced that the U.S. Food and Drug Administration has approved EPKINLY™ as the first and only T-cell engaging bispecific antibody for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B‑cell lymphoma, after two or more lines of systemic therapy.

Krystal Biotech, Inc. (the Company) (NASDAQ: KRYS), a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases, today announced the US Food and Drug Administration (FDA) has approved VYJUVEK™ (beremagene geperpavec-svdt) for the treatment of patients six months of age or older with dystrophic epidermolysis bullosa (DEB).

Research from Eascra Biotech will be onboard Axiom Mission 2, a private crew mission to the International Space Station set to launch Sunday May 21 from Kennedy Space Station.

400 million people around the world are affected by a rare disease. 95% of rare diseases lack an FDA approved treatment or cure.

Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM) today announced the Company will release its first quarter 2023 financial results after the U.S. financial markets close on Monday, May 22, 2023.

Calyxt, Inc. announced the results of the special meeting of its stockholders held on May 18, 2023.

Forte Biosciences, Inc., a biopharmaceutical company focused on autoimmune diseases, announced the issuance of an equity inducement award as required by the Nasdaq Stock Market Rules.